Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men.

Richard E HaalandJeffrey FountainAmy MartinChuong DinhAngela HolderTiancheng E EdwardsL Davis LupoLaShonda HallChristopher Conway-WashingtonIvana MassudJ Gerardo García-LermaColleen F KelleyWalid M Heneine

Published in: The Journal of antimicrobial chemotherapy (2022)

Whereas bictegravir plasma concentrations persist at least 4 days after a two-oral-dose HIV prophylaxis regimen, elvitegravir accumulates in mucosal tissues. Differing elvitegravir and bictegravir distribution may result in variable mucosal and systemic antiviral activity and can inform dosing strategies for event-driven HIV prevention.

Keyphrases

antiretroviral therapy
ulcerative colitis
hiv infected
hiv positive
human immunodeficiency virus
hepatitis c virus
gene expression
hiv testing
hiv aids
middle aged
drug induced